ClinicalTrialsFinder
RecruitingNCT06851702

Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

100 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Hematological Malignancies

Summary

Retrospective / prospective observational study of endocrinological adverse events in hematologic patients treated with immunological checkpoint inhibitors

Eligibility

Min Age: 18 Years

Inclusion Criteria12

  • Retrospective cohort
  • patients aged> 18 years
  • cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
  • advanced stage of illness (relapsed or refractory)
  • patients undergoing treatment with immune anticheckpoint antibodies.
  • written informed consent
  • Prospective cohort
  • patients aged> 18 years
  • cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
  • advanced stage of illness (relapsed or refractory)
  • patients who are candidates for therapy with anticheckpoint immune antibodies (it is specified that this therapy is completely independent of the subject's participation in the study).
  • written informed consent

Exclusion Criteria1

  • Severe, acute and chronic medical or psychiatric disorders that may affect the interpretation of the study results or interfere with it.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

IRCCS Azienda Ospedaliero - Universitaria di Bologna

Bologna, Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06851702

Related Trials

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT0463455278 locations

Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology

NCT053065091 location

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

NCT072206164 locations

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT022695927 locations

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

NCT066526336 locations